About Warner Chilcott (NASDAQ:WCRX)
Warner Chilcott Public Limited Company is a specialty pharmaceutical company. The Company is focused on the women's healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. The Company's hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product, launched in January 2011, that offers women the lowest dosage of estrogen of any oral contraceptive available in the United States market. In October 2013, Actavis Inc acquired the entire share capital of Warner Chilcott PLC.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Warner Chilcott (NASDAQ:WCRX) Frequently Asked Questions
What is Warner Chilcott's stock symbol?
Warner Chilcott trades on the NASDAQ under the ticker symbol "WCRX."
Who are some of Warner Chilcott's key competitors?
Some companies that are related to Warner Chilcott include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly and (LLY), AstraZeneca (AZN), Celgene (CELG), GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHPG) and Shire (SHP).
How do I buy Warner Chilcott stock?
Shares of Warner Chilcott can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Warner Chilcott?
Warner Chilcott's mailing address is Grand Canal Square, DUBLIN,, Ireland. The specialty pharmaceutical company can be reached via phone at +353-1-8972000.
MarketBeat Community Rating for Warner Chilcott (WCRX)MarketBeat's community ratings are surveys of what our community members think about Warner Chilcott and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Warner Chilcott (NASDAQ:WCRX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Warner Chilcott (NASDAQ:WCRX) Earnings History and Estimates Chart
Warner Chilcott (NASDAQ WCRX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/24/2013||Q2 2013||$0.84||$0.92||$598.23 million||$613.00 million||View||N/A|
|5/10/2013||Q1 2013||$0.85||$0.45||$588.06 million||$593.00 million||View||N/A|
|2/22/2013||Q4 2012||$0.73||$0.50||$565.21 million||$612.00 million||View||N/A|
|11/9/2012||Q312||$0.77||$0.99||$595.96 million||$606.00 million||View||N/A|
Warner Chilcott (NASDAQ:WCRX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Warner Chilcott (NASDAQ:WCRX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Warner Chilcott (NASDAQ WCRX)
No insider trades for this company have been tracked by MarketBeat.com
Warner Chilcott (NASDAQ WCRX) News Headlines
Warner Chilcott (NASDAQ:WCRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Warner Chilcott (NASDAQ:WCRX) Income Statement, Balance Sheet and Cash Flow Statement
Warner Chilcott (NASDAQ WCRX) Stock Chart for Sunday, February, 18, 2018